Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin

被引:20
|
作者
Nishiyama, M
Itoh, F
Ujiie, A
机构
[1] Central Research Laboratories, Kissei Pharmaceutical Co., Ltd., Hotaka, Nagano 399-83, 4365-1, Kashiwabara
来源
JAPANESE JOURNAL OF PHARMACOLOGY | 1997年 / 74卷 / 01期
关键词
heparin; dalteparin sodium; bone metabolism; osteopenia;
D O I
10.1254/jjp.74.59
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the pharmacological effects of dalteparin (low-molecular-weight heparin) and heparin on bone metabolism in rats. After their 28 days of consecutive intravenous injections, significant loss of bone weight and mineral contents was observed in the heparin-treated rats, whereas dalteparin slightly reduced bone mass. By the end of the experiment, the femora of 7 out of 8 rats fractured in the heparin (10,000 U/kg/day)-treated group, but none had broken in the control and dalteparin-treated groups. Serum osteocalcin levels were significantly decreased in the former group. The growth plate width of the tibia was increased in a dose-dependent manner, especially in the heparin-treated group. Histomorphometric assessment of tibia showed that the osteoid surface and mineral apposition rates were significantly reduced in the heparin-treated group, whereas the eroded surface was significantly increased in the heparin-treated group. The above results suggest that heparin not only augments bone resorption but also suppressed bone formation and that dalteparin has a weaker suppressive effect on bone formation compared with heparin.
引用
收藏
页码:59 / 68
页数:10
相关论文
共 50 条
  • [1] Dalteparin: A low-molecular-weight heparin
    Howard, PA
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (02) : 192 - 203
  • [2] PHARMACOKINETICS OF A LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH STANDARD HEPARIN
    MATZSCH, T
    BERGQVIST, D
    HEDNER, U
    OSTERGAARD, P
    THROMBOSIS RESEARCH, 1986, : 118 - 118
  • [3] Anticoagulation with low-molecular-weight heparin dalteparin in atrial fibrillation
    Bechtold, H
    Sawitzki, H
    Gunzenhauser, D
    Janssen, D
    EUROPEAN HEART JOURNAL, 2000, 21 : 8 - 8
  • [4] Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy
    DeBernardo, RL
    Perkins, RB
    Littell, RD
    Krasner, CN
    Duska, LR
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (05): : 1006 - 1011
  • [5] Thromboprophylaxis with low molecular weight heparin (dalteparin) compared with unfractionated heparin in pregnancy.
    Kaaja, R
    Pettilä, V
    Leinonen, P
    Ikkala, E
    BLOOD, 1998, 92 (10) : 360A - 360A
  • [6] Heparin and low-molecular-weight heparin
    Gray, Elaine
    Mulloy, Barbara
    Barrowcliffel, Trevor W.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (05) : 807 - 818
  • [7] Localization of heparin and low-molecular-weight heparin in the rat kidney
    Young, E
    Douros, V
    Podor, TJ
    Shaughnessy, SG
    Weitz, JI
    THROMBOSIS AND HAEMOSTASIS, 2004, 91 (05) : 927 - 934
  • [8] EFFECTS OF LOW-MOLECULAR-WEIGHT HEPARIN ON PLATELETS AS COMPARED WITH COMMERCIAL HEPARIN
    CELLA, G
    SCATTOLO, N
    LUZZATTO, G
    GIROLAMI, A
    RESEARCH IN EXPERIMENTAL MEDICINE, 1984, 184 (04) : 227 - 229
  • [9] Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
    Vignoli, A
    Marchetti, M
    Balducci, D
    Barbui, T
    Falanga, A
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 207 - 214
  • [10] Inhibition of trypsin by heparin and dalteparin, a low molecular weight heparin
    Bosnic, Olivera M.
    Gopcevic, Kristina R.
    Vrvic, Miroslav M.
    Karadzic, Ivanka M.
    JOURNAL OF THE SERBIAN CHEMICAL SOCIETY, 2009, 74 (04) : 379 - 388